Andrea Flynn

Andrea joined ArcherDX in November 2019. Prior to joining ArcherDX, Andrea was head of Investor Relations and Corporate Communications for Array BioPharma, prior to its acquisition by Pfizer Inc. From 2015 to 2018, Andrea built and led the investor relations and communications functions at Novavax, Inc., a publicly-traded clinical-stage vaccine company. From 2013 to 2015, Andrea led investor relations and communications programs for a broad range of life sciences, biotech and biopharma companies as part of Russo Partners. Andrea received her Ph.D. in Cell Biology as part of an HHMI-funded, National Academy of Sciences laboratory at the University of Iowa and was a postdoctoral research scholar at Columbia University and the University of Arizona. She currently serves on the board of directors of the Cystic Fibrosis Foundation Rocky Mountain Chapter.